Shares of Biogen Inc. BIIB, -0.98% plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. 4523, -0.24% ESALY, -0.55% said Thursday they have decided to discontinue late-stage trials of a treatment for Alzheimer's disease, after an independent data monitoring committee said they were unlikely to meet its primary goal.
Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.
Source: News Formal (newsformal.com)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Source: Reuters - 🏆 2. / 97 Read more »
Biogen scraps Alzheimer drug trials, wiping $17 billion off its market valueReuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for t... This sucks. Did they forget? 😂
Source: Reuters - 🏆 2. / 97 Read more »
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
Source: CNBC - 🏆 12. / 72 Read more »
Biogen heads for the worst day in a decade after ending trial for blockbuster Alzheimer's drugShares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab. Literally no one expected it to be a blockbuster. No quick fix for Trump
Source: CNBC - 🏆 12. / 72 Read more »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
Source: MarketWatch - 🏆 3. / 97 Read more »
Biogen loses same Alzheimer’s bet others have lostThe failures of similar drugs in formal trials meant Biogen’s effort was always a long shot. Yet ditching it vaporized $18 bln, or over a quarter, of the biotech’s value. The giant market for a therapy and the fear of missing out lured in both the company and Wall Street. ReutersBiz rob_cyran This will continue to happen, again and again. Focus ought to be in industry and long-term planning, understanding of trends. Not in magic bullets and 24x5s.
Source: Breakingviews - 🏆 470. / 51 Read more »
Stocks making the biggest moves midday: Levi Strauss, Biogen, Micron & moreThese are the stocks posting the largest moves midday Thursday. Liberals trying to think about stocks
Source: CNBC - 🏆 12. / 72 Read more »
Here are the biggest analyst calls of the day: Biogen, Apple, Micron, & moreHere are the biggest calls on Wall Street on Thursday
Source: CNBC - 🏆 12. / 72 Read more »
Stocks making the biggest moves premarket: Biogen, Boeing, Walmart, Apple, Clorox & moreSome of the names on the move ahead of the open. mr_jettlife Average working class people should NEVER buy stocks. It's Gambling. The only people who make money in it are insiders and millionaires and billionaires.
Source: CNBC - 🏆 12. / 72 Read more »
Biogen is crashing after scrapping its late-stage Alzheimer's drug trialsBiogen shares crashed more than 25% in pre-market trading after discontinuing two late-stage Alzheimer's drug trials with Eisai.
Source: BusinessInsider - 🏆 729. / 51 Read more »